leadf
logo-loader
viewMedexus Pharmaceuticals Inc

Medexus says joint-disease drug added to public drug plans in four Canadian provinces

The drug has been approved for inclusion on the Alberta Drug Benefit List, the Saskatchewan Drug Plan, the Newfoundland and Labrador Prescription Drug Program, and the Yukon Drug Formulary  

Medexus Pharmaceuticals Inc - Medexus Pharmaceuticals Inc says joint-pain drug Triamcinolone Hexacetonide has been added to public drug plans in five Canadian provinces
The company is advancing the commercial rollout of Triamcinolone Hexacetonide in additional provinces

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) announced Thursday that its joint-disease drug Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been added to public drug plans in four Canadian provinces.

The drug has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, the Newfoundland and Labrador Prescription Drug Program (NLPDP), and the Yukon Drug Formulary for the treatment of Juvenile Idiopathic Arthritis (JIA). 

Also for public reimbursement, TH has been approved for inclusion on the Ontario Drug Benefit Formulary/Comparative Drug Index and the Non-Insured Health Benefits – Drug Benefit List for its full Health Canada-approved indication, which includes approved use in both adults and adolescents. 

READ: Medexus fiscal 4Q revenue soars following IXINITY hemophilia drug acquisition

TH is the longest acting corticosteroid for intra-articular injection, often lasting twice as long as comparator products, the company said. 

“The inclusion of our TH on these public drug plan formularies in Canada enhances the accessibility of this therapy for pediatric and adult patients suffering from chronic inflammatory diseases including JIA and RA (rheumatoid arthritis),” said Ken d’Entremont, Medexus CEO, in a statement.

“Previously, both younger and adult patients with subacute and chronic inflammatory joint diseases have had difficulty getting TH due to a long-standing shortage of Triamcinolone Hexacetonide in Canada.”

He also noted that the company is advancing the commercial rollout of TH in additional provinces.

“Moreover, we believe our formulation has the potential to become the standard of care for the treatment of many severe joint diseases, as it significantly impacts the safety and cost-effectiveness of treatment by providing longer duration of action, with fewer injections, compared to other corticosteroid injections and intra-articular steroids,” d’Entremont added.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

 

Quick facts: Medexus Pharmaceuticals Inc

Price: 3.83 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $55.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Medexus Pharmaceuticals gets Health Canada approval to market Gleolan for...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) CEO Ken d’Entremont tells Proactive the group has received a notice of compliance from Health Canada, granting the company approval to market its tumor imaging agent Gleolan in the country. d’Entremont says with Gleolan, which is essentially...

2 weeks, 3 days ago

2 min read